Researchers in Toronto (Bruce Perkins MD) and Montreal (Ahmad Haidar PhD) and their teams have started the “Closed Loop ASSessment 17 (CLASS17)” study investigating how a pill used for the management of type 2 diabetes can help a hybrid closed loop insulin pump system work better to achieve time-in-target blood sugar levels for those with type 1 diabetes. The pill is a type of Sodium-Glucose Linked Transporter (SGLT) inhibitor that lowers blood sugar by increasing the urinary excretion of sugar. The hybrid closed loop system uses a Dexcom sensor, a Tandem insulin pump, and the McGill Artificial Pancreas algorithm run on an Android phone.

For more information about the study, see https://clinicaltrials.gov/ct2/show/NCT03979352?term=CLASS17&rank=1 or e-mail Class17@lunenfeld.ca